

RARE DISEASES IN THE LIMELIGHT

Research attention on rare diseases is expanding, with renewed hope for novel therapeutic and diagnostic modalities in recent years. Historically, garnering scientific interest was a challenge, primarily because of funding deficits for small, widely disbursed patient populations. As a mobile, in-home solutions company, we are perfectly suited to access otherwise hard-to-reach rare disease patients across the United States. Indeed, we are increasingly contracted for translational and clinical studies across this disease group. By partnering with us, you would be giving the patients you advocate for an opportunity to participate in potentially life-changing research—regardless of where they live.



Sanguine

PRIVACY AND PROTECTION

The protection of patient health data is vital in each and every research endeavor and we ensure that all practices and protocols are HIPAA-compliant and IRB-approved. We maintain the privacy and confidentiality of all health records—shared only across select internal staff members and study personnel of the consented study.

Our model is centered around valuing our patient community's autonomy and privacy, and we focus extensively on protecting and enhancing their health. Our informed consent protocol is 21 CFR 11-compliant; our organization maintains the gold standard AAHRPP accreditation for protecting research participants, and we exceed standards set by GCP guidelines.

HIPPA
compliant

IRB
approved

AAHRPP
accredited

21 CFR 11
compliant

Partner Highlights



CONTACT US
partners@sanguinebio.com



LEARN MORE
<https://patients.sanguinebio.com/>

References

1. Landy DC, Brinich MA, Colten ME, et al. How disease advocacy organizations participate in clinical research: a survey of genetic organizations. *Genet Med.* 2012;14(2):223–228.
2. Gallin EK, Bond E, Califf RM, et al. Forging stronger partnerships between academic health centers and patient-driven organizations. *Acad Med.* 2013;88(9):1220–1224.



Empowering Patients in Biomedical Research Together

patients.sanguinebio.com

Who We Are and What We Do?

We empower patients in biomedical research. By participating, patients can help researchers discover new treatments and speed up the drug development process related to their condition. We function to provide the pharmaceutical industry with an enhanced ability to recruit study participants and collect biospecimens and data through a mobile workforce across the United States. Our key advantage – our mobile approach – brings research participation into the patient's home with a primary focus on establishing trustworthy relationships.

We currently partner with more than 100 patient advocacy and non-profit groups to reach the most eligible participants for each research study we support. As a valued partner in our effort to advance science, we regularly support our patient advocacy partners with monetary donations to further enrich the educational resources they provide. Our relationships are mutually beneficial and built upon representing and engaging with patients to make valuable research accessible to all.

Studies show that communication and outreach are amongst the most important factors for study recruitment and completion.^{1,2} And direct patient engagement across all stages of research is paramount in our approach to facilitating its success. By working together, we can strengthen the platform of collaborative biomedical research. Ours is a patient-centered synergy that is poised to drive scientific innovation and discovery to improve the lives of the patients we serve.

Why Partner with Sanguine?

Patient advocacy and non-profit group partnerships are invaluable to our commitment to equipping patients with opportunities to join scientists at the forefront of biomedical research. In turn, we provide researchers with the ability to create improved study designs with the highest likelihood of success. Together, we have a positive impact on all stakeholders.

PATIENT EMPOWERMENT

We engage with patients to provide them with added tools and knowledge to further their understanding of disease and all the facets related to translational and clinical research processes. We continuously source published work for communicating results and advancements made, thereby adding value to the patient's contribution. We take a collaborative approach, connecting extensively with patients, advocacy groups, and researchers to leverage seamless and synergistic energy across all stakeholders. Ultimately, our patient communities are at the forefront of our approach, and we exist to improve their lives with hopes of easing disease burden across many conditions.



9.6 PHLEBOTOMIST EXPERIENCE

9.6 PATIENT SATISFACTION SCORE

9.7 COORDINATOR EXPERIENCE

PATIENT CONVENIENCE

Our virtual recruitment and in-home collection capabilities are designed to be minimally disruptive to patients' everyday lives. As a result, patient retention is consistently high (93%) across each study we support. Moreover, a high proportion of patients are eager to participate again and over long study periods, meaning the high scientific value of completing longitudinal studies can be realized. By working with researchers to improve study completion and success rates, we minimize inconclusive findings and wasted funding, which further motivates patients to embark on the quest toward improved outcomes.



100% INTERNALLY SOURCED AND TRAINED STAFF

99% PATIENT RECALL RATE

93% STUDY RETENTION RATE